Piper Sandler Initiates Regeneron with 'Overweight' Rating on Oncology Growth

Piper Sandler has initiated coverage on Regeneron Pharmaceuticals (REGN) with an 'Overweight' rating, highlighting the company's growth potential in oncology. Analysts expect Regeneron's advancements in cancer treatments to positively impact its stock performance. Piper Sandler's assessment is based on Regeneron's current drug portfolio and its pipeline of oncology products. The firm notes that the company's immuno-oncology efforts could generate significant revenue contributions in the coming period. Analysts state that Regeneron's strong R&D pipeline and commercial success position it favorably compared to industry peers. Piper Sandler emphasizes that these factors create a positive outlook for the stock. This is not investment advice.

📊 REGN — Piyasa Yorumu

▲ up · 65%

Piper Sandler's positive recommendation could bring buying interest to the stock in the short term. Technical indicators also support this view; the RSI is above 60 and the MACD is trending positively above the signal line. The price is trading above the 20- and 50-day moving averages. However, following the rise in the last 24 hours, some profit-taking may occur in the short term. Therefore, the upward expectation can be expressed with moderate confidence.

RSI 14

60.5

MACD

3.56

24h Δ

2.68%

Canlı Grafikler